MBX

Investing.com — Three major investment firms started research coverage of MBX Biosciences stock on Tuesday, each assigning a Buy rating to the biotechnology company. Analysts at Jefferies highlighted the potential of MBX’s lead program, MBX-2109, which is currently in Phase II trials for hypoparathyroidism. They expressed confidence in the company’s…